In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:
- Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
- Evaluating the future impact of key items when reviewing a biotech IP portfolio
- Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
- Valuation methodologies used for early-stage vs. late-stage products
Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.
Related Insights
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence…
May 28, 2025
Foley Viewpoints
U.S. and International Antitrust Agencies Signal Aggressive Antitrust Enforcement in Procurement, Consumer Products, and Labor Markets
As we previously reported on April 15 and April 28, the Department of Justice (DOJ) and Federal Trade Commission (FTC) are increasingly…
May 28, 2025
Foley Career Perspectives
Foley AANHPI Heritage Month Program: A Conversation With Crypto Journalist Laura Shin
In celebration of Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month, Foley & Lardner hosted a firmwide…